Genetics In The News

Interleukin Genetics Cites Role in Key Antisense Drug Trial Published in The Lancet

Interleukin’s Genetic Test Patterns Provide Key Genetic Data in Clinical Studies

WALTHAM, Mass., September 22, 2016 — Interleukin Genetics, Inc. (OTCQB: ILIU) a life science company focused on the genetics of chronic inflammation, today announced their contribution to the key publication in The Lancet (September 21, 2016) of the article “Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomized, double blind, placebo-controlled, dose ranging trials.” The article provides strong evidence that the antisense drug IONIS-APO(a)-LRX is well tolerated and capable of achieving substantial reductions in Lp(a) concentrations in patients. The drug is intended, in part, to reduce the risk for secondary cardiovascular events in individuals with elevated Lp(a).

“This prestigious publication shows the potential for Interleukin-1 genetic variations […]

Interleukin’s PerioPredict® Genetic Test Featured in Genome Magazine

Interleukin Leads the Way in Personalized Dentistry

WALTHAM, Mass. – January 5, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced that an article, titled “Dentistry Gets Personalized,” has been published online in Genome magazine.  The article, which also appeared in the Fall 2014 print issue, includes an overview of Interleukin’s novel genetic test, PerioPredict®, and its utility in identifying a patient’s risk for severe periodontal disease based on the individual’s genetic profile as well as its role in advancing personalized medicine in dentistry.

The full article can be accessed online here.

PerioPredict® works by measuring variations in the genes for Interleukin-1 (IL-1), a key mediator of inflammation, and identifies individuals who are at an increased risk for more severe periodontal disease, […]

Perspectives on FDA Letter to 23andMe

On November 22, 2013, the FDA issued a Warning Letter to 23andMe instructing the company to halt sales of its genetic tests due to failure to obtain regulatory clearance. 

23andMe claims in its company literature that it collects DNA directly from consumers, analyzes those samples for over one million SNPs across the entire genome and provides risk information back to the consumer on more than 240 conditions and diseases, including several cancers, Alzheimer’s disease, and other major medical conditions. 

The Food and Drug Administration (FDA) has repeatedly stated that it has the authority to regulate laboratory-developed tests, or LDTs, but has generally exercised enforcement discretion in not otherwise regulating LDTs that are validated by and performed only in a high complexity […]